| HOME >> MEDICINE >> TECHNOLOGY |
Hematological Cancer Therapies: A Prelude 3
Treatment Regimes: The Golden Rule 4
Multiple Myeloma: A Second Most Common Hematological Cancer 5
Treatment Therapies: Move Up the Learning Curve 6
Risk-Adapted Therapy: The New Norm of Future Treatment 7
New Generation Drugs in the Arsenal Against Multiple Myeloma 7
Velcade® (Bortezomib) 7
Thalomid® (Thalidomide) 7
Revlimid® (Lenalidomide) 8
Alkeran (Melphalan) 8
Doxil (Liposomal Doxorubicin) 9
Trisenox® (Arsenic trioxide) 9
Noteworthy Issues Related to Major Drugs: An Evaluation of
Pros and Cons 9
Revlimid Overtakes Thalomid: Why? 9
How Effective Will Thalomid Be in the 3rd Line Setting?
Skepticism Overflows 10
Revlimid Impedes Stem Cell Harvesting!!: What's the Truth? 10
1st & 2nd Generation Geldanamycin Analog to Do Wonders for
Myeloma Treatment 10
Other Trends & Issues 11
Approval of New Generation Drugs Push the Market Into the
Bulge Bracket 11
Growth Fundamentals Get Stronger 11
Multidrug Resistance: A Challenge to Reckon With 12
Gene Therapy Exudes Hope 12
Challenges Encountered in Clinical Trials 12
FDA's Antidotes 13
Europe Lagging Behind in Drug Approvals 14
Market Share Statistics 15
Oncology and Hematology Market 16
Drugs Approved & In Pipeline: A Review 16
Multiple Myeloma Drugs Approved by the FDA As of the Year 2008 16
Multiple Myeloma Drugs in Pipeline in the US As of the Year
Phase III Drugs in Pipeline 17
Phase II Drugs in Pipeline 18
Phase I Drugs in Pipeline 25
Key Non-Profit Organizations in the US 29
Multiple Myeloma Research Foundat
'/>"/>
| SOURCE Reportlinker Copyright©2009 PR Newswire. All rights reserved |